Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Bull-like who wrote (8232)	10/19/1999 4:05:00 PM
From: Frank Brisebois	Read Replies (1) \| Respond to of 9523

ALL: At the close of the bell, someone bought 112,900 shares at 40... Frank

To: Bull-like who wrote (8232)	10/19/1999 4:39:00 PM
From: Anthony Wong	Respond to of 9523

Analyst ratings/comments today: (Bloomberg) Pfizer Inc. (PFE US) was reiterated ''buy'' by analyst Carl J. Seiden at J.P. Morgan Securities. (Bloomberg) Pfizer Inc. (PFE US) was raised to ''buy'' from ''market perform'' by analyst Barbara A. Ryan at Deutsche Banc Alex. Brown. (CBS MarketWatch) Co. says it will let revs. go to bottom line, is restraining spending. (Bloomberg) Pfizer Inc. (PFE US) was reiterated ''outperform'' by analyst James P. Keeney at ABN Amro. The 12-month target price is $45.00 per share. (Bloomberg) ''For Pfizer, it's not just one product,'' said Jeffrey Chaffkin, an analyst with PaineWebber, who has a ''buy'' rating on Pfizer. '' They've got Viagra, they've got Lipitor and they've got Celebrex. At the same time, Pfizer has been able to boost sales of its older products such as Zoloft and Norvasc. Pfizer now faces the challenge of following up on these successes. It will review its pharmaceutical research at a November analyst meeting. ''The issue for them is what they will have to show us in November,'' Chaffkin said.